| Identification | Back Directory | [Name]
4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- | [CAS]
2231294-96-3 | [Synonyms]
ODM208
Opevesostat
2-(Isoindolin-2-ylmethyl)-5-[[1-(methylsulfonyl)-4-piperidyl]methoxy]-4H-pyran-4-one
4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- | [Molecular Formula]
C21H26N2O5S | [MOL File]
2231294-96-3.mol | [Molecular Weight]
418.51 |
| Chemical Properties | Back Directory | [Boiling point ]
611.2±65.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
6.28±0.20(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Opevesostat (MK-5684; ODM-208) is an orally active and selective CYP11A1 inhibitor. Opevesostat has the potential for the research of metastatic castration-resistant prostate cancer (mCRPC)[1]. | [References]
[1] Fizazi, K. et al. 1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results. Annals of Oncology, Volume 35, S968. |
|
|